Oric Pharmaceuticals News and Activities
Presence
Oric Pharmaceuticals develops cancer medicines for patients with advanced cancers. Its work focuses on targeted therapies and clinical drug programs for healthcare providers, researchers, and patients.
Oric Pharmaceuticals products and services overview:
- Cancer therapeutics
- Targeted therapies
- Clinical research
- Drug discovery
Revenue: ~$0 million
Employees: 130
Headquarters: South San Francisco, United States (USA)
Oric Pharmaceuticals is one of the...
Oric Pharmaceuticals is a company listed under the stock ticker ORIC (US).
Executives
View the org chart displaying its 30 main executives
Most searched biographies at Oric Pharmaceuticals
- Jacob Chacko, Chief Executive Officer and Director
- Angie You, Director
- Richard Heyman, Chairman of the Board
Popular executive movements at Oric Pharmaceuticals
- Jeffrey Frazier, Director, Regulatory Affairs, has left the company (posted on April 17 2026).
- Christian Dimaano has joined the company as Vice President, Head of Medical Affairs (posted on April 17 2026).
Create your alert
to follow the executive moves at Oric Pharmaceuticals.
Pharmaceuticals
Oric Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Oric Pharmaceuticals
- ORIC Pharmaceuticals to Present at the Jefferies Healthcare Conference | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Announces Presentation of Preclinical Data on Glucocorticoid Receptor Antagonist Overcoming Resistance to an Androgen Receptor Degrader at the 32nd EORTC-NCI-AACR Symposium 2020 | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Reports Second Quarter 2020 Financial and Operational Update | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive Worldwide License to Highly Selective Allosteric PRC2 Inhibitors from Mirati Therapeutics | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals to Host Second Quarter 2020 Financial Results Conference Call | ORIC Pharmaceuticals, Inc.
- ORIC Pharmaceuticals Presents Preclinical Data on Glucocorticoid Receptor Antagonist and CD73 Inhibitor Programs at the 2020 American Association for Cancer Research Virtual Annual Meeting II | ORIC Pharmaceuticals, Inc.
- View more press releases Close
Social media about Oric Pharmaceuticals
- Oric Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Oric Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
